Aptinyx Inc. (APTX)
|52 Week Range||0.05-0.72|
|1y Target Est||-|
|DCF Unlevered||APTX DCF ->|
|DCF Levered||APTX LDCF ->|
|Debt / Equity||148.86%||Buy|
Upgrades & Downgrades
Latest APTX news
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
30 March 2023
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate re...
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
21 March 2023
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Why Is Aptinyx (APTX) Stock Down 64% Today?
28 February 2023
Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary ...
Aptinyx to Present at the SVB Securities Global Biopharma Conference
31 January 2023
EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...
Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
8 November 2022
Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO ...
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
18 October 2022
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
12 August 2022
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript
7 August 2022
Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - Pres...
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
15 July 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to...